Abstract

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafenib is becoming increasingly common. This study aims to identify factors contributing to resistance and ways to mitigate resistance. Recent studies have shown that epigenetics, transport processes, regulated cell death, and the tumor microenvironment are involved in the development of sorafenib resistance in HCC and subsequent HCC progression. This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients.

Details

Title
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
Author
Tang, Weiwei 1 ; Chen, Ziyi 2 ; Zhang, Wenling 3 ; Cheng, Ye 1 ; Zhang, Betty 4 ; Wu, Fan 1 ; Wang, Qian 1   VIAFID ORCID Logo  ; Wang Shouju 5 ; Rong Dawei 2 ; Reiter, F P 6 ; De Toni E N 6 ; Wang, Xuehao 2 

1  Nanjing Medical University, Department of General Surgery, Nanjing First Hospital, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984) 
2  Chinese Academy of Medical Sciences, Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Nanjing, China (GRID:grid.477246.4) 
3  The First Affiliated Hospital of Nanjing Medical University, Department of Gastroenterology, Nanjing, China (GRID:grid.412676.0) (ISNI:0000 0004 1799 0784) 
4  McMaster University, Michael G. DeGroote School of Medicine, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227) 
5  The First Affiliated Hospital of Nanjing Medical University, Department of Radiology, Nanjing, China (GRID:grid.412676.0) (ISNI:0000 0004 1799 0784) 
6  University Hospital, LMU, Department of Medicine II, Munich, Germany (GRID:grid.477246.4); University Hospital, LMU, Liver Center Munich, Munich, Germany (GRID:grid.477246.4) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41392-020-0187-x
ProQuest document ID
2412412807
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.